Please ensure Javascript is enabled for purposes of website accessibility

Anika Therapeutics Beats Revenue and Earnings Estimates

By Taylor Carmichael – Feb 21, 2020 at 11:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.

Anika Therapeutics (ANIK 0.04%) delivered its fourth-quarter earnings report Thursday night, beat Wall Street's consensus estimates on both the top and bottom lines

The medical technology company, which focuses on the $7 billion sports and regenerative medicine market, offers products that address a continuum of medical issues from arthritis pain management to joint restoration. 

For the quarter, Anika reported sales of $29.77 million, up 10% from the previous year, and profits of $0.43 a share, down from $0.54 a share a year ago.  But earnings were expected to be lower this quarter because of the costs associated with its acquisition of Parcus Medical and Arthrosurface, and the launch of a new product, Tactoset, an injectable bone substitute. 

X-ray of knees

Image source: Getty Images

Recovering from the death of its CEO

Joe Darling, the company's president and CEO, recently died from an unspecified medical condition. Cheryl Blanchard was named interim chief executive officer. On the conference call, she said: "I'd like to start by remembering Anika's President and CEO, Joe Darling, who passed away unexpectedly on Jan. 29. When I interviewed to join Anika's Board, Joe talked about Anika and the people who make up Anika with a passion you hope every leader exhibits about his or her company. Joe was a wonderful leader and a trusted colleague, who led the beginning of our transformation into a global commercial company. Over the last two and a half years, he set Anika on its current path reinforcing its strong foundation, leveraging its strengths and embracing innovation." 

Darling was instrumental in the acquisition of Parcus Medical and Arthrosurface, as well as the launch of Tactoset, the company's first surgical orthopedic product. For 2020, the company is forecasting $3 million in revenues from Tactoset. 

Shares were up slightly in early trading Friday.

Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Anika Therapeutics, Inc. Stock Quote
Anika Therapeutics, Inc.
ANIK
$23.47 (0.04%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.